Efficacy of Bulleyaconitine A combined with pregabalin in the treatment of herpes zoster neuralgia and its effects on serum neuropeptide, IL-17, CXCL10 and NF-κB levels
10.3760/cma.j.cn431274-20240801-01179
- VernacularTitle:草乌甲素联合普瑞巴林治疗带状疱疹神经痛的疗效及对血清神经肽、IL-17、CXCL10和NF-κB水平的影响
- Author:
Zhifeng ZHANG
1
;
Wenlu YAN
1
;
Ziwei XIA
1
;
Kemei SHI
1
Author Information
1. 天津医科大学第二医院疼痛治疗中心，天津 300211
- Publication Type:Journal Article
- Keywords:
Herpes zoster neuralgia;
Bulleyaconitine A;
Pregabalin;
Neuropeptide;
Inflammation
- From:
Journal of Chinese Physician
2025;27(7):999-1003
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical efficacy of Bulleyaconitine A combined with pregabalin in the treatment of herpes zoster neuralgia (HZN), and its effects on serum neuropeptide, interleukin-17 (IL-17), CXC chemokine ligand 10 (CXCL10), and nuclear factor-κB (NF-κB) levels.Methods:A total of 114 HZN patients admitted to the Second Hospital of Tianjin Medical University from January 2021 to December 2022 were selected and divided into observation group ( n=57) and control group ( n=57) by random number table method. The control group was treated with oral pregabalin capsules, and the observation group was treated with Bulleyaconitine A on the basis of the control group for 4 weeks. The clinical efficacy of the two groups was observed. The Visual Analogue Scale (VAS) score for pain, total score of Pittsburgh Sleep Quality Index (PSQI), total score of The MOS 36 Item Short form Health Survey (SF-36), as well as serum neuropeptide [substance P (SP), neuropeptide Y (NPY), β-endorphin (β-EP)] and IL-17, CXCL10, NF-κB levels were compared between the two groups before and after treatment. The occurrence of adverse reactions in the two groups was recorded. Results:The total effective rate of the observation group [82.46%(47/57)] was significantly higher than that of the control group [64.91%(37/57), P<0.05]. Before treatment, there were no significant differences in VAS score, total PSQI score, and total SF-36 score between the two groups (all P>0.05); after treatment, the VAS score and total PSQI score of both groups were significantly decreased (all P<0.05), the total SF-36 score was significantly increased (all P<0.05), and the above indicators in the observation group were better than those in the control group (all P<0.05). Before treatment, there were no significant differences in serum SP, NPY, and β-EP levels between the two groups (all P>0.05); after treatment, serum SP and NPY levels in both groups were significantly decreased (all P<0.05), serum β-EP levels were significantly increased (all P<0.05), and serum SP and NPY levels in the observation group were lower than those in the control group (all P<0.05), serum β-EP levels were higher than those in the control group ( P<0.05). Before treatment, there were no significant differences in serum IL-17, CXCL10, and NF-κB levels between the two groups (all P>0.05); after treatment, serum IL-17, CXCL10, and NF-κB levels in both groups were significantly decreased (all P<0.05), and serum IL-17, CXCL10, and NF-κB levels in the observation group were lower than those in the control group (all P<0.05). There was no significant difference in the adverse reaction rate between the observation group [7.02%(4/57)] and the control group [12.28%(7/57)] ( P>0.05). Conclusions:Bulleyaconitine A combined with pregabalin has good efficacy and safety in the treatment of HZN, which can effectively reduce the degree of neuropathic pain and improve sleep and quality of life. Its mechanism may be related to further regulating the level of neuropeptide and inhibiting the inflammatory state in the body.
